Alpelisib (PIQRAY, Novartis Pharmaceuticals Corporation), a PI3K inhibitor, received FDA approval in combination with fulvestrant for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative PIK3CA-mutated advanced breast cancer. The gene discussed is PIK3CA; the disease is breast cancer.